A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer
Latest Information Update: 11 Jul 2024
At a glance
- Drugs Sacituzumab govitecan (Primary) ; Docetaxel; Paclitaxel; Vinflunine
- Indications Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms TROPiCS-04
- Sponsors Gilead Sciences; Immunomedics
- 30 May 2024 According to a Gilead Sciences Media Release, data from this study will be presented at an upcoming medical meeting.
- 30 May 2024 Primary endpoint (Overall Survival (OS)) has not been met, according to a Gilead Sciences Media Release.
- 30 May 2024 Results presented in a Gilead Sciences Media Release.